Research Overview

Tirzepatide

Tirzepatide (GLP-2T / dual GIP-GLP-1 receptor agonist)

A dual incretin-receptor agonist, one of the most extensively studied peptides in metabolic research.

What It Is

Tirzepatide is a synthetic 39-amino-acid peptide engineered to act on two incretin receptor systems at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual-agonist design distinguishes it from single-target GLP-1 receptor agonists studied earlier in the incretin literature.

It is among the most rigorously published peptides referenced on this site, with large randomized controlled trials in the peer-reviewed literature characterizing its receptor pharmacology, a research base that makes it a frequently cited reference compound in metabolic and incretin signaling studies.

Mechanism in the Research Literature

Published pharmacology research describes tirzepatide as a balanced agonist at both the GIP and GLP-1 receptors, engineered from a GIP backbone with modifications enabling GLP-1 receptor activity. Studies have examined how combined engagement of both incretin pathways produces signaling effects distinct from GLP-1 agonism alone, a central question in the dual-agonist literature.

Research has also characterized its extended pharmacokinetic profile, attributed to a fatty-acid moiety that promotes albumin binding, a design approach shared with other long-acting peptide therapeutics studied in this class.

Why Purity Verification Matters Here

A 39-residue peptide with a conjugated fatty-acid moiety has considerably more synthesis complexity than a short linear peptide, which means more points where a batch can deviate from the intended sequence. HPLC purity data alone does not confirm that the fatty-acid conjugation site is correct; mass spectrometry is needed to verify overall molecular identity. Third-party, lot-specific verification is the standard for treating a tirzepatide reference sample as equivalent to what the published literature describes.

Third-party tested. Lot-matched. No exceptions.

Every unrl batch is characterized by independent third-party testing before it ships, not just an in-house spec sheet. Each Certificate of Analysis is tied to the lot number printed on the vial, so what you're holding matches a specific, published result rather than a generic average.

Independent lab, not manufacturer self-testing
HPLC purity + mass spectrometry identity confirmation
Lot-specific CoA, matched to the vial in hand
Published and searchable in the public COA library

View the COA Library

Research Use Only

This page is provided for research and educational purposes only. The compound discussed is a research reference standard, not a dietary supplement, drug, or article for human or veterinary use. Nothing on this page is medical advice, dosing guidance, or a claim of safety or efficacy. No statement has been evaluated by the FDA.

Quick Reference